1. Tannock IF, Goldenberg GG. Drug resistance and experimental chemotherapy. In: The Basic Science of Oncology, 3rd edition, IF Tannock, RP Hill (eds.), McGraw-Hill, New York, NY, 392–419, 1998.
2. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys, 5:85–91, 1979.
3. Britten RA, Warenius HM. De novo cisplatinum resistance does not influence cellular radiosensitivity. Eur J Cancer, 29A:1315–1320, 1993.
4. Britten RA, Evans AJ, Allalunis-Turner MJ, Pearcey RG. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys, 34:367–374, 1996.
5. Warenius HM, Seabra LA, Maw P. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin DI but not c-raf-1 protein. Int J Cancer, 67:224–231, 1996.